171 related articles for article (PubMed ID: 38001635)
1. Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study.
Dicitore A; Gaudenzi G; Carra S; Cantone MC; Oldani M; Saronni D; Borghi MO; Grotteschi J; Persani L; Vitale G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001635
[TBL] [Abstract][Full Text] [Related]
2. Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.
Carra S; Gaudenzi G; Dicitore A; Cantone MC; Plebani A; Saronni D; Zappavigna S; Caraglia M; Candeo A; Bassi A; Persani L; Vitale G
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897702
[TBL] [Abstract][Full Text] [Related]
3. Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids.
Giandomenico V; Cui T; Grimelius L; Öberg K; Pelosi G; Tsolakis AV
J Mol Endocrinol; 2013 Dec; 51(3):277-86. PubMed ID: 23969981
[TBL] [Abstract][Full Text] [Related]
4. Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
Bayat Mokhtari R; Baluch N; Morgatskaya E; Kumar S; Sparaneo A; Muscarella LA; Zhao S; Cheng HL; Das B; Yeger H
BMC Cancer; 2019 Aug; 19(1):864. PubMed ID: 31470802
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
6.
Lee HG; Lim GH; An JH; Park SM; Seo KW; Youn HY
J Vet Sci; 2024 Jan; 25(1):e1. PubMed ID: 38311316
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
Cella CA; Cazzoli R; Fazio N; De Petro G; Gaudenzi G; Carra S; Romanenghi M; Spada F; Grossi I; Pallavicini I; Minucci S; Vitale G
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37855330
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
Fiebiger W; Olszewski U; Ulsperger E; Geissler K; Hamilton G
Clin Transl Oncol; 2011 Jan; 13(1):43-9. PubMed ID: 21239354
[TBL] [Abstract][Full Text] [Related]
9. The cytotoxic effect of emetine and CGP-74514A studied with the hollow fiber model and ArrayScan assay in neuroendocrine tumors in vitro.
Larsson DE; Hassan SB; Oberg K; Granberg D
Anticancer Agents Med Chem; 2012 Sep; 12(7):783-90. PubMed ID: 22263790
[TBL] [Abstract][Full Text] [Related]
10. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.
Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer.
Saronni D; Gaudenzi G; Dicitore A; Carra S; Cantone MC; Borghi MO; Barbieri A; Mignani L; Hofland LJ; Persani L; Vitale G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139603
[TBL] [Abstract][Full Text] [Related]
12. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
[TBL] [Abstract][Full Text] [Related]
15. Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.
Hanley KZ; Dureau ZJ; Cohen C; Shin DM; Owonikoko TK; Sica GL
Cancer Cytopathol; 2018 Apr; 126(4):236-242. PubMed ID: 29316326
[TBL] [Abstract][Full Text] [Related]
16. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
[TBL] [Abstract][Full Text] [Related]
17. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
18. Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.
Mokhtari RB; Qorri B; Baluch N; Sparaneo A; Fabrizio FP; Muscarella LA; Tyker A; Kumar S; Cheng HM; Szewczuk MR; Das B; Yeger H
Oncotarget; 2021 Jul; 12(15):1470-1489. PubMed ID: 34316328
[TBL] [Abstract][Full Text] [Related]
19. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
20. Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.
Reddy VG; Reddy TS; Jadala C; Reddy MS; Sultana F; Akunuri R; Bhargava SK; Wlodkowic D; Srihari P; Kamal A
Eur J Med Chem; 2019 Nov; 182():111609. PubMed ID: 31445229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
